Currently, chemotherapeutic treatment approaches, such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) and targeted treatments such as Ibrutinib (BTK inhibitor) and Venetoclax (BCL2 inhibitor) are used to treat MCL. This evidence concerns the gene BTK and mantle cell lymphoma.